|

Cabozantinib S-malate Clinical Trials

9 actively recruiting trials across 6 locations

Also known as: BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184

Birmingham, Alabama2 trials

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Children's Hospital of Alabama

Phase 2/3
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

University of Alabama at Birmingham Cancer Center

Phase 2

Irvine, California2 trials

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1/2

Atlanta, Georgia2 trials

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University Hospital Midtown

Phase 2

Phoenix, Arizona1 trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Mayo Clinic Hospital in Arizona

Phase 2

Houston, Texas1 trial

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M D Anderson Cancer Center

Phase 1

Salt Lake City, Utah1 trial

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Huntsman Cancer Institute/University of Utah

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.